Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabergoline

FDA-approved product (tablet, oral), marketed as Cabergoline, Dostinex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cabergoline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypothalamic neoplasm
  • Parkinson disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prolactine inhibitors; Dopamine agonists
FDA pharmacologic class
Ergot Derivative FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabergoline in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabergoline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

    NCT03928288 · start 2019-12-02

    Registered record
    Registry ID
    NCT03928288
    Conditions
    Endometriosis
    Interventions
    Cabergoline 0.5 MG; Placebo - Cap
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-12-02
    Completion
    2026-01-14
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionCabergoline 0.5 MG; Placebo - Cap
    PhasePhase 2
    Registry statusCompleted

  • Satisfaction of Patients With the Chosen Method of Inhibition of Lactation

    NCT04038749 · start 2019-06-16

    Registered record
    Registry ID
    NCT04038749
    Conditions
    Lactation Suppressed
    Interventions
    Bromocriptine; Cabergoline; Natural methods
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-06-16
    Completion
    2022-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactation Suppressed
    InterventionBromocriptine; Cabergoline; Natural methods
    PhaseNot applicable
    Registry statusUnknown

  • Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)

    NCT03714763 · start 2018-11-01

    Registered record
    Registry ID
    NCT03714763
    Conditions
    Pituitary Adenoma
    Interventions
    Drug treatment; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-11-01
    Completion
    2022-01-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPituitary Adenoma
    InterventionDrug treatment; Surgery
    PhaseNot applicable
    Registry statusUnknown

  • Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas

    NCT03400865 · start 2018-10-25

    Registered record
    Registry ID
    NCT03400865
    Conditions
    Resistance, Disease; Prolactinoma
    Interventions
    HCQ/CQ and CAB combined treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-10-25
    Completion
    2020-12-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionResistance, Disease; Prolactinoma
    InterventionHCQ/CQ and CAB combined treatment
    PhaseNot applicable
    Registry statusUnknown

  • Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility

    NCT03549741 · start 2018-07

    Registered record
    Registry ID
    NCT03549741
    Conditions
    Infertility
    Interventions
    Clomiphene Citrate 50mg; Cabergoline Oral Tablet; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2018-07
    Completion
    2019-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionClomiphene Citrate 50mg; Cabergoline Oral Tablet; Placebo Oral Tablet
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

    NCT03457389 · start 2018-02-22

    Registered record
    Registry ID
    NCT03457389
    Conditions
    Pituitary Adenoma; Prolactinoma; Pituitary Tumor; Recurrence Tumor
    Interventions
    Cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-02-22
    Completion
    2024-12-31
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPituitary Adenoma; Prolactinoma; Pituitary Tumor; Recurrence Tumor
    InterventionCabergoline
    PhaseNot applicable
    Registry statusUnknown

  • The Influence of Timing of Cabergoline Initiation on Prevention of OHSS

    NCT02620605 · start 2017-12-20

    Registered record
    Registry ID
    NCT02620605
    Conditions
    Ovarian Hyperstimulation Syndrome
    Interventions
    Late Cabergoline 0.5mg; Early Cabergoline 0.5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-12-20
    Completion
    2019-04
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Hyperstimulation Syndrome
    InterventionLate Cabergoline 0.5mg; Early Cabergoline 0.5mg
    PhasePhase 3
    Registry statusUnknown

  • Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

    NCT03313661 · start 2017-10-14

    Registered record
    Registry ID
    NCT03313661
    Conditions
    Diabetes
    Interventions
    Cabergoline; Gliclazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-10-14
    Completion
    2020-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    InterventionCabergoline; Gliclazide
    PhasePhase 3
    Registry statusUnknown

  • Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome

    NCT02875587 · start 2016-10

    Registered record
    Registry ID
    NCT02875587
    Conditions
    OHSS
    Interventions
    Cabergoline; Calcium gluconate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-10
    Completion
    2018-12
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOHSS
    InterventionCabergoline; Calcium gluconate
    PhasePhase 2
    Registry statusCompleted

  • Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

    NCT02542410 · start 2016-05

    Registered record
    Registry ID
    NCT02542410
    Conditions
    Endometriosis
    Interventions
    Cabergoline; Norethindrone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-05
    Completion
    2018-09
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionCabergoline; Norethindrone acetate
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

    NCT02685709 · start 2016-02

    Registered record
    Registry ID
    NCT02685709
    Conditions
    Acromegaly
    Interventions
    Octreotide capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02
    Completion
    2021-08
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionOctreotide capsules
    PhasePhase 3
    Registry statusCompleted

  • Cabergoline in Nonfunctioning Pituitary Adenomas

    NCT03271918 · start 2015-02-01

    Registered record
    Registry ID
    NCT03271918
    Conditions
    Pituitary Adenoma; Nonfunctioning Pituitary Adenoma
    Interventions
    Cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2017-08-01
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPituitary Adenoma; Nonfunctioning Pituitary Adenoma
    InterventionCabergoline
    PhasePhase 3
    Registry statusCompleted

  • Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection

    NCT02306564 · start 2014-12

    Registered record
    Registry ID
    NCT02306564
    Conditions
    Infertility
    Interventions
    Cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2014-12
    Completion
    2017-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionCabergoline
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

    NCT02288962 · start 2014-11

    Registered record
    Registry ID
    NCT02288962
    Conditions
    Pituitary Neoplasms; Adenoma
    Interventions
    cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2014-11
    Completion
    2028-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPituitary Neoplasms; Adenoma
    Interventioncabergoline
    PhasePhase 3
    Registry statusActive not recruiting

  • Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention

    NCT03473613 · start 2014-10-01

    Registered record
    Registry ID
    NCT03473613
    Conditions
    Ovarian Hyperstimulation
    Interventions
    Oral Cabergoline; Calcium Gluconate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10-01
    Completion
    2017-04-15
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Hyperstimulation
    InterventionOral Cabergoline; Calcium Gluconate
    PhasePhase 3
    Registry statusCompleted